Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Procept

Executive Summary

Cambridge, Massachusetts-based immunologic drug R&D firm signs five-year collaborative R&D agreement with Bristol-Myers Squibb supporting Procept collaborative research with Ellis Reinherz at the Dana-Farber Cancer Institute. Bristol-Myers Squibb will have exclusive worldwide rights to therapeutic applications of the proprietary receptor technology to combat autoimmune disease and organ transplant rejection, and Procept has retained certain manufacturing and marketing rights to the products. In a separate transaction, Bristol made "a minority equity investment" in Procept.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS017169

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel